Ainos, Inc. (NASDAQ:AIMD) Short Interest Update

Ainos, Inc. (NASDAQ:AIMD) was the target of a significant increase in short interest in May. As of May 29th, there was short interest totaling 91,823 shares, an increase of 289.3% from the May 14th total of 23,588 shares. Based on an average daily volume of 2,248,715 shares, the short-interest ratio is presently 0.0 days. Approximately 1.2% of the company’s stock are short sold.

Insider Transactions at Ainos

In other news, Director Chun-Jung Tsai sold 27,718 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $1.87, for a total transaction of $51,832.66. Following the transaction, the director directly owned 658,199 shares of the company’s stock, valued at approximately $1,230,832.13. The trade was a 4.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ting-Chuan Lee sold 109,988 shares of the business’s stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $1.90, for a total transaction of $208,977.20. Following the transaction, the director directly owned 807,417 shares in the company, valued at approximately $1,534,092.30. The trade was a 11.99% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have bought 7,800 shares of company stock valued at $15,946 and have sold 179,788 shares valued at $359,247. Corporate insiders own 9.79% of the company’s stock.

Hedge Funds Weigh In On Ainos

Several institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC grew its position in shares of Ainos by 13.1% during the fourth quarter. Renaissance Technologies LLC now owns 66,300 shares of the company’s stock worth $109,000 after acquiring an additional 7,700 shares during the last quarter. DRW Securities LLC grew its position in shares of Ainos by 272.6% during the fourth quarter. DRW Securities LLC now owns 66,211 shares of the company’s stock worth $109,000 after acquiring an additional 48,439 shares during the last quarter. Two Sigma Investments LP bought a new position in shares of Ainos during the third quarter worth about $80,000. Finally, Mariner LLC bought a new position in shares of Ainos during the fourth quarter worth about $37,000.

Ainos Stock Performance

Shares of NASDAQ:AIMD traded down $0.01 on Friday, reaching $1.91. 25,851 shares of the company’s stock were exchanged, compared to its average volume of 1,049,508. The firm has a market capitalization of $16.27 million, a price-to-earnings ratio of -0.66 and a beta of 2.41. Ainos has a fifty-two week low of $1.26 and a fifty-two week high of $4.50. The business’s 50-day moving average is $1.84 and its two-hundred day moving average is $1.81. The company has a quick ratio of 0.50, a current ratio of 0.55 and a debt-to-equity ratio of 1.58.

Ainos (NASDAQ:AIMD) last issued its earnings results on Wednesday, May 13th. The company reported ($0.41) earnings per share for the quarter. Ainos had a negative return on equity of 160.55% and a negative net margin of 11,912.10%.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of Ainos from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, May 26th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

Ainos Company Profile

Ainos, Inc (NASDAQ: AIMD) is a clinical?stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company’s proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations.

The lead product candidate, AI?401, is an inhaled formulation of ibuprofen in a dry powder format.